Prestige Brands Holdings was founded in 1996 and is headquartered in Irvington, New York. Prestige Brands Holdings, Inc. (Prestige) sells over-the-counter healthcare, household cleaning and personal care products in a global marketplace. The Company’s products are sold through multiple channels, including mass merchandisers and drug, grocery, dollar and club stores, which allow it to launch products across all distribution channels and reduce its exposure to any single distribution channel. The Company conducts its operations through three principal business segments: over-the-counter healthcare, household cleaning and personal care. During the fiscal year ended March 31, 2009 (fiscal 2009), Prestige’s principal brands accounted for approximately 94.5% of its net revenues.

Mirari Biosciences was founded in 2000 by CEO Mark Martin, who developed the MASC and Peplica technologies. Mirari Biosciences it working to cut down on the time its takes to test new drugs. The first of the company's two primary technologies is microwave-accelerated surface chemistry (MASC) which can speed up drug discovery tests, medical and veterinary diagnostics, and food and water testing by exposing test materials to low-heat microwaves. Its protein amplification technology (Peplica) replicates proteins which helps researchers locate and identify minute levels of proteins.

Formerly known as Stone Electronic Technology Limited, Stone Group Holdings Limited (Stock code: 409) was established on September 3, 1987. After a successful restructuring exercise in 1993, the Company became the first non-state-owned share-holding company in the PRC listed on the Stock Exchange of Hong Kong in August 1993. It is principally engaged in IT electronic & media – related business in mainland China, healthcare products business and investment business.The Company's IT electronic and media-related business includes the manufacture and distribution of traditional electronic products and the operation of internet café chain. Electronic products include dot matrix printer and value-added tax control machine with patented intellectual property, and the Group also acts as the agent and distributor of industrial controllers, uninterrupted power system equipment, digital graphics, semiconductors, computers etc.. Product coverage includes SIEMENS, FUJI. The internet café chain – Sunnet café is located in Guangdong Province.

Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

NextGen Group, which does business as NextGen Sciences, puts proteins to the test. The research and development company provides protein analysis services for biotechnology and pharmaceutical customers around the world. Specific services include biomarker discovery and assay development, which are often used in the drug development process to test preclinical and clinical samples for therapeutic efficacy and safety. NextGen's biomarker projects focus on Alzheimer's disease and oncology, among other therapeutic areas. The group has operations in the US and the UK.

MerseyBIO is an incubator for young biotechnology businesses. Backed by the University of Liverpool and National Health Service, the company provides office and laboratory space, as well as business, investment, and technical support services to biotechnology entrepreneurs. MerseyBIO, which can incubate up to 15 biotechnology businesses, also networks its member biotechnology companies with other biotechnology firms and resources around the world. Provexis plc became the first flotation of a MerseyBIO-based company.

Warnex Inc., a life sciences company, provides laboratory services to the pharmaceutical and healthcare sectors in Canada, the United States, and internationally. The company’s Analytical Services division provides quality control services, including chemistry, chromatography, microbiology, method development and validation, and stability studies to pharmaceutical, biotechnology, cosmetics, and veterinary industries. This division offers a range of ICH stability conditions and provides stability management, and revalidates existing methods to ensure compliance with regulatory requirements and performs technology transfers. Its Bioanalytical Services division offers a range of services to the pharmaceutical and biotechnology industries. It specializes in bioavailability and bioequivalence studies, as well as provides services in the areas of research and development, method development, validation, production, and quality assurance.This division helps companies in their drug development programs by carrying out analyses generated in pre-clinical studies and proceeding with evaluation of the drug in human clinical trials. It also provides services to generic drug industry by analyzing physiological fluid samples obtained from studies in humans. The company’s Medical Laboratories division provides specialized laboratory services to the healthcare sector. It offers Prenatest prenatal screening test, which enables pregnant women to find out their risk of carrying a fetus that may be affected by common birth anomalies. This division also provides PRO-DNATM paternity test; genetic testing for human identification, molecular diagnostics, and pharmacogenetics; and testing services in the areas of endocrinology, hematology, infectious diseases, obstetrics/gynecology, and oncology. The company was formerly known as Warnex Pharma, Inc. and changed its name to Warnex Inc. in June 2001. Warnex Inc. was founded in 1996 and is headquartered in Laval, Canada.

Hikma Pharmaceuticals was founded in 1978 by chairman Samih Darwazah. Hikma Pharmaceuticals Plc is a speciality pharmaceutical company with operations in Europe and the United States and a focus in the Middle East and North Africa (MENA) region. The Company develops, manufactures and markets branded and unbranded generic, as well as in-licensed products in both oral and injectable dosage forms. Its operations are conducted through three segments: Branded Pharmaceuticals, Generic Pharmaceuticals and Injectable Pharmaceuticals. Hikma Pharmaceuticals Plc’s Branded Pharmaceuticals segment develops, manufactures and markets 241 solid, semi-solid and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 products under-license from the originator. Injectable Pharmaceuticals segment develops, manufactures and markets 81 injectable products in 202 dosage strengths. Generic Pharmaceuticals develops, manufactures and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms.

CardioVascular BioTherapeutics, Inc. (Cardio) is a development-stage biopharmaceutical company focused on developing drugs to stimulate the growth of new blood vessels for the treatment of cardiovascular diseases. The active pharmaceutical ingredient (API) in the Company’s drug candidates is acidic human fibroblast growth factor-1, FGF-1141 (formerly called Cardio Vascu-Grow) and it facilitates the growth of new blood vessels in the heart tissues and organs with an impaired vascular system. This process is referred to as angiogenesis in the scientific community. The Company’s research and development is focused on developing new drug candidates, in which FGF-1141 is the API for the treatment of cardiovascular diseases, where the growth of new blood vessels can improve the outcome for patients. The Company conducts research to identify and evaluate medical indications that may benefit from its drug candidates.

DRAXIS Specialty Pharmaceuticals (formerly DRAXIS Health) lights up your insides with its own radiopharmaceuticals, but its main business is making other drug companies' injectable drugs, lotions and pills. The company's larger DRAXIS Pharma unit is a contract manufacturer specializing in liquid and freeze-dried injectable drugs, though it also makes sterile and non-sterile ointments, creams, and other formulations. Another unit, DRAXIMAGE, develops and makes radiopharmaceuticals, such as radioactive iodine, for use in diagnostic and therapeutic nuclear medicine procedures. DRAXIMAGE sells its products mostly in the US and Canada. In 2008 India-based Jubilant Organosys acquired DRAXIS for about $255 million.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.